Korro Bio, Inc. reported revenue growth to $6.4 million in 2025 alongside deepening operating losses of approximately $122 million, reflective of its development-stage status investing heavily in R&D. The company's proprietary RNA editing platform, OPERA®, remains central to its strategy amid typical biotech risks. A recent $85 million PIPE financing extends Korro's cash runway into late 2028, supporting ongoing clinical development and operational needs. Management's November 2025 workforce reduction aims to optimize resources while maintaining focus on advancing pipeline candidates.